Avramides A, Flores A, DeRose J, Wallach S
J Clin Endocrinol Metab. 1976 Mar;42(3):459-63. doi: 10.1210/jcem-42-3-459.
Thirteen patients with Paget's disease of the bone were treated with subcutaneous injections of synthetic salmon calcitonin (SCT) for a mean period of 22 months at doses of 50-100 MCR units daily or 3 times a week. They manifested symptomatic improvement and significant reductions in serum alkaline phosphatase and urinary hydroxyproline excretion during SCT administration. Following discontinuation of SCT, symptomatic improvement was maintained in 10 patients for up to one year, whereas a recurrence of symptoms was seen in only 3 patients. The serum alkaline phosphatase generally showed a return toward pretreatment values 6 months after discontinuation of SCT, whereas urinary hydroxyproline remained depressed for up to a year.
13例骨佩吉特病患者接受皮下注射合成鲑鱼降钙素（SCT）治疗，平均疗程22个月，剂量为每日50 - 100 MCR单位或每周3次。在给予SCT期间，患者症状改善，血清碱性磷酸酶和尿羟脯氨酸排泄量显著降低。停用SCT后，10例患者症状改善维持长达1年，而仅3例患者出现症状复发。停用SCT 6个月后，血清碱性磷酸酶一般恢复至治疗前水平，而尿羟脯氨酸水平在长达1年的时间里仍保持较低水平。
